{"generic":"Antihemophilic Factor VIII (Recombinant)","drugs":["Antihemophilic Factor VIII (Recombinant)","Helixate FS","Kogenate FS","Kogenate FS with BIO-SET","Novoeight","Recombinate","Refacto"],"mono":{"0":{"id":"924955-s-0","title":"Generic Names","mono":"Antihemophilic Factor VIII (Recombinant)"},"1":{"id":"924955-s-1","title":"Dosing and Indications","sub":[{"id":"924955-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Bleeding, Routine prophylaxis - Hemophilia A:<\/b> (Kogenate(R)) 25 international units\/kg IV 3 times per week<\/li><li><b>Bleeding, Routine prophylaxis - Hemophilia A:<\/b> (Novoeight(R)) 20 to 50 international units\/kg IV 3 times per week, OR 20 to 40 international units\/kg IV every other day<\/li><li><b>Bleeding, Short-term spontaneous musculoskeletal; Prophylaxis - Hemophilia A:<\/b> In clinical studies, the mean doses per infusion for routine prophylaxis were 29 +\/- 11 international units\/kg for previously treated patients, ages 8 to 73 years, and 53 +\/- 22 international units\/kg for treatment-naive patients, ages less than 1 to 52 months. Dosing frequency of 3 times per week may be preferable to twice weekly<\/li><li><b>Bleeding - Hemophilia A:<\/b> dosage calculation: body weight (kg) X 0.5 international units\/kg X factor VIII activity increase desired (%) = dose required (international units)<\/li><li><b>Bleeding - Hemophilia A:<\/b> Helixate(R) FS and Kogenate(R) FS: minor hemorrhage, 10 to 20 international units\/kg to achieve increase in plasma level of antihemophilic factor of 20% to 40% of normal; repeat dose if evidence of further bleeding<\/li><li><b>Bleeding - Hemophilia A:<\/b> Helixate(R) FS and Kogenate(R) FS: moderate to major hemorrhage, 15 to 30 international units\/kg to achieve increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat one dose at 12 to 24 hours if needed<\/li><li><b>Bleeding - Hemophilia A:<\/b> Helixate(R) FS and Kogenate(R) FS: major to life-threatening hemorrhage, fractures, head trauma, initially 40 to 50 international units\/kg to achieve increase in plasma level of antihemophilic factor of 80% to 100% of normal; repeat dose 20 to 25 international units\/kg every 8 to 12 hours<\/li><li><b>Bleeding - Hemophilia A:<\/b> Novoeight(R) and Recombinate(TM): minor hemorrhage, increase in plasma level of antihemophilic factor of 20% to 40% of normal, begin infusions every 12 to 24 hours for 1 to 3 days until the bleeding episode is resolved (as indicated by relief of pain) or healing is achieved<\/li><li><b>Bleeding - Hemophilia A:<\/b> Novoeight(R) and Recombinate(TM): moderate hemorrhage, increase in plasma level of antihemophilic factor of 30% to 60% of normal, repeat infusion every 12 to 24 hours for usually 3 days or more until pain and disability are resolved<\/li><li><b>Bleeding - Hemophilia A:<\/b> Novoeight(R) and Recombinate(TM): major hemorrhage, increase in plasma level of antihemophilic factor of 60% to 100% of normal, repeat infusions every 8 to 24 hours until resolution of the bleeding episode has occurred<\/li><li><b>Bleeding - Hemophilia A:<\/b> ReFacto(R): minor hemorrhage, increase in plasma level of antihemophilic factor of 20% to 40% of normal; repeat dose every 12 to 24 hours for at least 1 day depending on severity<\/li><li><b>Bleeding - Hemophilia A:<\/b> ReFacto(R): moderate hemorrhage, increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat dose every 12 to 24 hours for at 3 to 4 days until hemostasis is achieved<\/li><li><b>Bleeding - Hemophilia A:<\/b> ReFacto(R): major hemorrhage, increase in plasma level of antihemophilic factor of 60% to 100% of normal every 8 to 24 hours until hemostasis is achieved<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> dosage calculation: body weight (kg) X 0.5 international units\/kg X factor VIII activity increase desired (%) = dose required (international units)<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Helixate(R) FS and Kogenate(R) FS: minor surgery, 15 to 30 international units\/kg to achieve increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat one dose at 12 to 24 hours if needed<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Helixate(R) FS and Kogenate(R) FS: major surgery, preoperative dose 50 international units\/kg to achieve increase in plasma level of antihemophilic factor of 100% of normal; repeat as necessary after 6 to 12 hours initially and for 10 to 14 days until complete healing<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Novoeight(R): minor surgery (including tooth extraction), increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat infusions every 24 hours for at least 1 day until healing is achieved<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Novoeight(R): major surgery, increase in plasma level of antihemophilic factor of 80% to 100% of normal; repeat infusions every 8 to 24 hours until adequate wound healing, then continue for at least 7 days to maintain factor VIII activity of 30% to 60%<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Recombinate(TM): minor surgery (including tooth extraction), single bolus infusion to achieve increase in plasma level of antihemophilic factor of 60% to 80% of normal, plus oral antifibrinolytic therapy beginning within 1 hour of the operation<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Recombinate(TM): major surgery, increase in plasma level of antihemophilic factor of 80% to 100% of normal (pre-and-post operative); repeat infusions every 8 to 24 hours, depending on state of wound healing<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> ReFacto(R): minor surgery, increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat dose every 12 to 24 hours for at 3 to 4 days until hemostasis is achieved<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> ReFacto(R): tooth extraction, single infusion to increase in plasma level of antihemophilic factor of 30% to 60% of normal plus oral antifibrinolytic therapy within 1 hours may be sufficient for hemostasis<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> ReFacto(R): major surgery, increase in plasma level of antihemophilic factor of 60% to 100% of normal, repeat every 8 to 24 hours until hemostasis is achieved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> dosage calculation: body weight (kg) X 0.5 international units\/kg X factor VIII activity increase desired (%) = dose required (international units)<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Helixate(R) FS and Kogenate(R) FS: minor hemorrhage, 10 to 20 international units\/kg to achieve increase in plasma level of antihemophilic factor of 20% to 40% of normal; repeat dose if evidence of further bleeding<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Helixate(R) FS and Kogenate(R) FS: moderate to major hemorrhage, 15 to 30 international units\/kg to achieve increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat one dose at 12 to 24 hours if needed<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Helixate(R) FS and Kogenate(R) FS: major to life-threatening hemorrhage, fractures, head trauma, initially 40 to 50 international units\/kg to achieve increase in plasma level of antihemophilic factor of 80% to 100% of normal; repeat dose 20 to 25 international units\/kg every 8 to 12 hours<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Recombinate(TM): minor hemorrhage, increase in plasma level of antihemophilic factor of 20% to 40% of normal, begin infusions every 12 to 24 hours for 1 to 3 days until the bleeding episode is resolved (as indicated by relief of pain) or healing is achieved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Recombinate(TM): moderate hemorrhage, increase in plasma level of antihemophilic factor of 30% to 60% of normal, repeat infusion every 12 to 24 hours for usually 3 days or more until pain and disability are resolved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Recombinate(TM): major hemorrhage, increase in plasma level of antihemophilic factor of 60% to 100% of normal, repeat infusions every 8 to 24 hours until resolution of the bleeding episode has occurred<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> ReFacto(R): minor hemorrhage, increase in plasma level of antihemophilic factor of 20% to 40% of normal; repeat dose every 12 to 24 hours for at least 1 day depending on severity<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> ReFacto(R): moderate hemorrhage, increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat dose every 12 to 24 hours for at 3 to 4 days until hemostasis is achieved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> ReFacto(R): major hemorrhage, increase in plasma level of antihemophilic factor of 60% to 100% of normal every 8 to 24 hours until hemostasis is achieved<\/li><\/ul>"},{"id":"924955-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Bleeding, Joint damage; Prophylaxis - Hemophilia A:<\/b> 25 international units\/kg IV every other day<\/li><li><b>Bleeding, Routine prophylaxis - Hemophilia A:<\/b> (Kogenate(R)) 25 international units\/kg IV every other day<\/li><li><b>Bleeding, Routine prophylaxis - Hemophilia A:<\/b> (Novoeight(R)) younger than 12 years, 25 to 60 international units\/kg IV 3 times per week, OR 25 to 50 international units\/kg IV every other day<\/li><li><b>Bleeding, Routine prophylaxis - Hemophilia A:<\/b> (Novoeight(R)) 12 years or older, 20 to 50 international units\/kg IV 3 times per week, OR 20 to 40 international units\/kg IV every other day<\/li><li><b>Bleeding, Short-term spontaneous musculoskeletal; Prophylaxis - Hemophilia A:<\/b> In clinical studies, the mean doses per infusion for routine prophylaxis were 29 +\/- 11 international units\/kg for previously treated patients, ages 8 to 73 years, and 53 +\/- 22 international units\/kg for treatment-naive patients, ages less than 1 to 52 months. Dosing frequency of 3 times per week may be preferable to twice weekly<\/li><li><b>Bleeding - Hemophilia A:<\/b> dosage calculation: body weight (kg) X 0.5 international units\/kg X factor VIII activity increase desired (%) = dose required (international units)<\/li><li><b>Bleeding - Hemophilia A:<\/b> Helixate(R) FS and Kogenate(R) FS: minor hemorrhage, 10 to 20 international units\/kg to achieve increase in plasma level of antihemophilic factor of 20% to 40% of normal; repeat dose if evidence of further bleeding<\/li><li><b>Bleeding - Hemophilia A:<\/b> Helixate(R) FS and Kogenate(R) FS: moderate to major hemorrhage, 15 to 30 international units\/kg to achieve increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat one dose at 12 to 24 hours if needed<\/li><li><b>Bleeding - Hemophilia A:<\/b> Helixate(R) FS and Kogenate(R) FS: major to life-threatening hemorrhage, fractures, head trauma, initially 40 to 50 international units\/kg to achieve increase in plasma level of antihemophilic factor of 80% to 100% of normal; repeat dose 20 to 25 international units\/kg every 8 to 12 hours<\/li><li><b>Bleeding - Hemophilia A:<\/b> Novoeight(R) and Recombinate(TM): minor hemorrhage, increase in plasma level of antihemophilic factor of 20% to 40% of normal, begin infusions every 12 to 24 hours for 1 to 3 days until the bleeding episode is resolved (as indicated by relief of pain) or healing is achieved<\/li><li><b>Bleeding - Hemophilia A:<\/b> Novoeight(R) and Recombinate(TM): moderate hemorrhage, increase in plasma level of antihemophilic factor of 30% to 60% of normal, repeat infusion every 12 to 24 hours for usually 3 days or more until pain and disability are resolved<\/li><li><b>Bleeding - Hemophilia A:<\/b> Novoeight(R) and Recombinate(TM): major hemorrhage, increase in plasma level of antihemophilic factor of 60% to 100% of normal, repeat infusions every 8 to 24 hours until resolution of the bleeding episode has occurred<\/li><li><b>Bleeding - Hemophilia A:<\/b> ReFacto(R): minor hemorrhage, increase in plasma level of antihemophilic factor of 20% to 40% of normal; repeat dose every 12 to 24 hours for at least 1 day depending on severity<\/li><li><b>Bleeding - Hemophilia A:<\/b> ReFacto(R): moderate hemorrhage, increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat dose every 12 to 24 hours for at 3 to 4 days until hemostasis is achieved<\/li><li><b>Bleeding - Hemophilia A:<\/b> ReFacto(R): major hemorrhage, increase in plasma level of antihemophilic factor of 60% to 100% of normal every 8 to 24 hours until hemostasis is achieved<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> dosage calculation: body weight (kg) X 0.5 international units\/kg X factor VIII activity increase desired (%) = dose required (international units)<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Helixate(R) FS and Kogenate(R) FS: minor surgery, 15 to 30 international units\/kg to achieve increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat one dose at 12 to 24 hours if needed<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Helixate(R) FS and Kogenate(R) FS: major surgery, preoperative dose 50 international units\/kg to achieve increase in plasma level of antihemophilic factor of 100% of normal; repeat as necessary after 6 to 12 hours initially and for 10 to 14 days until complete healing<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Novoeight(R): minor surgery (including tooth extraction), increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat infusions every 24 hours for at least 1 day until healing is achieved<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Novoeight(R): major surgery, increase in plasma level of antihemophilic factor of 80% to 100% of normal; repeat infusions every 8 to 24 hours until adequate wound healing, then continue for at least 7 days to maintain factor VIII activity of 30% to 60%<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Recombinate(TM): minor surgery (including tooth extraction), single bolus infusion to achieve increase in plasma level of antihemophilic factor of 60% to 80% of normal, plus oral antifibrinolytic therapy beginning within 1 hour of the operation<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> Recombinate(TM): major surgery, increase in plasma level of antihemophilic factor of 80% to 100% of normal (pre-and-post operative); repeat infusions every 8 to 24 hours, depending on state of wound healing<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> ReFacto(R): minor surgery, increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat dose every 12 to 24 hours for at 3 to 4 days until hemostasis is achieved<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> ReFacto(R): tooth extraction, single infusion to increase in plasma level of antihemophilic factor of 30% to 60% of normal plus oral antifibrinolytic therapy within 1 hours may be sufficient for hemostasis<\/li><li><b>Bleeding - Hemophilia A - Surgical procedure:<\/b> ReFacto(R): major surgery, increase in plasma level of antihemophilic factor of 60% to 100% of normal, repeat every 8 to 24 hours until hemostasis is achieved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> dosage calculation: body weight (kg) X 0.5 international units\/kg X factor VIII activity increase desired (%) = dose required (international units)<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Helixate(R) FS and Kogenate(R) FS: minor hemorrhage, 10 to 20 international units\/kg to achieve increase in plasma level of antihemophilic factor of 20% to 40% of normal; repeat dose if evidence of further bleeding<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Helixate(R) FS and Kogenate(R) FS: moderate to major hemorrhage, 15 to 30 international units\/kg to achieve increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat one dose at 12 to 24 hours if needed<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Helixate(R) FS and Kogenate(R) FS: major to life-threatening hemorrhage, fractures, head trauma, initially 40 to 50 international units\/kg to achieve increase in plasma level of antihemophilic factor of 80% to 100% of normal; repeat dose 20 to 25 international units\/kg every 8 to 12 hours<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Recombinate(TM): minor hemorrhage, increase in plasma level of antihemophilic factor of 20% to 40% of normal, begin infusions every 12 to 24 hours for 1 to 3 days until the bleeding episode is resolved (as indicated by relief of pain) or healing is achieved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Recombinate(TM): moderate hemorrhage, increase in plasma level of antihemophilic factor of 30% to 60% of normal, repeat infusion every 12 to 24 hours for usually 3 days or more until pain and disability are resolved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> Recombinate(TM): major hemorrhage, increase in plasma level of antihemophilic factor of 60% to 100% of normal, repeat infusions every 8 to 24 hours until resolution of the bleeding episode has occurred<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> ReFacto(R): minor hemorrhage, increase in plasma level of antihemophilic factor of 20% to 40% of normal; repeat dose every 12 to 24 hours for at least 1 day depending on severity<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> ReFacto(R): moderate hemorrhage, increase in plasma level of antihemophilic factor of 30% to 60% of normal; repeat dose every 12 to 24 hours for at 3 to 4 days until hemostasis is achieved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> ReFacto(R): major hemorrhage, increase in plasma level of antihemophilic factor of 60% to 100% of normal every 8 to 24 hours until hemostasis is achieved<\/li><li><b>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL:<\/b> immune tolerance induction: low-dose antihemophilic factor 25 to 50 international units\/kg every other day or 3 times a week has been used to obtain immune tolerance; high-dose antihemophilic factor 200 international units\/kg daily has also been used and was comparable to the low-dose regimen in immune tolerance achievement rates or time to tolerance achievement<\/li><\/ul>"},{"id":"924955-s-1-6","title":"Dose Adjustments","mono":"<b>(Novoeight(R), Kogenate(R) FS) pediatric patients:<\/b> higher or more frequent dosing based on body weight may be necessary due to increased clearance "},{"id":"924955-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bleeding, Joint damage; Prophylaxis - Hemophilia A<\/li><li>Bleeding, Routine prophylaxis - Hemophilia A<\/li><li>Bleeding, Short-term spontaneous musculoskeletal; Prophylaxis - Hemophilia A<\/li><li>Bleeding - Hemophilia A<\/li><li>Bleeding - Hemophilia A - Surgical procedure<\/li><li>Factor VIII inhibitor disorder, inhibitor titers less than 10 Bethesda Units\/mL<\/li><\/ul>"}]},"3":{"id":"924955-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924955-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to antihemophilic factor VIII or to any product component<\/li><li>hypersensitivity to mouse or hamster protein  or any other product component<\/li><li>hypersensitivity to bovine protein<\/li><\/ul>"},{"id":"924955-s-3-10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- hypersensitivity reactions, including anaphylaxis, may occur; discontinue if symptoms develop<\/li><li>-- diminished clinical response may be indicative of factor VIII inhibitor (neutralizing antibody) formation; monitoring recommended<\/li><li>-- young children with severe hemophilia at increased risk of factor VIII inhibitor (neutralizing antibody) formation during the first years of treatment<\/li><li>-- very young children have increased risk of allergic or anaphylactic reaction<\/li><li>-- hypersensitivity to antihemophilic factor concentrates increases risk of cross-sensitivity reaction to recombinant product<\/li><li>-- minimal previous exposure to antihemophilic factor increases risk of factor VIII inhibitor (neutralizing antibody) formation<\/li><\/ul>"},{"id":"924955-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"924955-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"924955-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension (1%)<\/li><li><b>Dermatologic:<\/b>Infection of central venous catheter (Pediatrics, 18% to 19%), Injection site reaction (Adult and pediatrics, 2.3% to 7%), Pruritus (1.8%), Rash (1%), Urticaria (1%)<\/li><li><b>Gastrointestinal:<\/b>Disorder of taste (2.7%), Nausea (1% to 4.4%)<\/li><li><b>Hepatic:<\/b>Increased liver enzymes (1.4%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Dizziness (3.5%), Headache (3.5%)<\/li><li><b>Other:<\/b>Factor VIII inhibitor disorder (31.7%), Fever (0.9% to 5.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis, Antibody development (Pediatrics, 12.5% to 15%)<\/li><li><b>Respiratory:<\/b>Dyspnea (1.8%)<\/li><\/ul>"},"6":{"id":"924955-s-6","title":"Drug Name Info","sub":{"0":{"id":"924955-s-6-17","title":"US Trade Names","mono":"<ul><li>Helixate FS<\/li><li>Kogenate FS<\/li><li>Kogenate FS with BIO-SET<\/li><li>Novoeight<\/li><li>Recombinate<\/li><li>Refacto<\/li><\/ul>"},"2":{"id":"924955-s-6-19","title":"Class","mono":"Antihemophilic Agent<br\/>"},"3":{"id":"924955-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924955-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"924955-s-7","title":"Mechanism Of Action","mono":"Recombinant antihemophilic Factor VIII is not derived from human blood, it is a glycoprotein produced by recombinant technology from Baby Hamster Kidney cells  or Chinese Hamster Ovary cells. Recombinant antihemophilic factor VIII temporarily replaces the missing clotting factor VIII necessary for hemostasis in patients with hemophilia A.<br\/>"},"8":{"id":"924955-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"924955-s-8-24","title":"Distribution","mono":"<ul><li>Vd, adult: 44.3 to 53.4 mL\/kg<\/li><li>Vd, pediatric: 55.8 to 57.3 mL\/kg (0 to less than 6 years); 41.2 to 57.3 mL\/kg (6 to less than 12 years)<\/li><\/ul>"},"3":{"id":"924955-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance, adult: 2.87 to 3.74 mL\/hr\/kg<\/li><li>Total body clearance, pediatric: 3.7 to 6.26 mL\/hr\/kg<\/li><\/ul>"},"4":{"id":"924955-s-8-27","title":"Elimination Half Life","mono":"<ul><li>adult, 10.8 to 12 hours  to 14.8 hours<\/li><li>pediatric, 7.7 to 10 hours<\/li><\/ul>"}}},"9":{"id":"924955-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>ReFacto(R) contains polysorbate 80, which increases the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC) containers.<\/li><li>Allow vials and diluent to reach room temperature prior to reconstitution.<\/li><li>After adding the diluent, swirl the contents until powder is dissolved.<\/li><li>(Helixate(R) FS, Kogenate(R) FS, Recombinate(TM), Refacto(R)) solution should be administered within 3 hours following reconstitution.<\/li><li>(Novoeight(R)) Administer within 4 hours of reconstitution at room temperature.<\/li><li>(Novoeight(R)) Prior to administration, attach prefilled diluent syringe to a Luer-lock compatible device (ie, a standard Luer-lock connector); If administering through an incompatible need&le;ss connector, withdraw reconstituted solution into a 10-mL, sterile Luer-lock plastic syringe.<\/li><li>(Kogentate(R) FS) Use administration set provided (includes inline filter) or use separate compatible filter when infusing into a peripheral or central line.<\/li><li>(Helixate(R) FS) Administer over 5 to 10 minutes or less and adjust rate as tolerated by the patient.<\/li><li>(Kogenate(R)FS) Administer IV over 1 to 15 minutes and adjust rate as tolerated.<\/li><li>(Novoeight(R)) Administer IV over 2 to 5 minutes.<\/li><li>(Recombinate(TM)) Administer up to a rate of 10 mL\/min and adjust to patient's comfort level.<\/li><li>(ReFacto(R)) Infuse over several minutes and adjust rate based on patient's comfort level.<\/li><\/ul>"},"10":{"id":"924955-s-10","title":"Monitoring","mono":"<ul><li>plasma factor VIII levels (serial); to determine adequate response, especially in the setting of surgical prophylaxis or severe bleeding<\/li><li>factor VIII inhibitor (neutralizing antibodies) levels; if inadequate response to appropriate doses<\/li><li>prevention or control of bleeding episodes are indicative of efficacy<\/li><li>clinical signs and symptoms of factor VIII inhibitor formation<\/li><li>pulse rate; prior to and during administration<\/li><li>blood pressure; decrease may be indicator of allergic reaction<\/li><\/ul>"},"11":{"id":"924955-s-11","title":"How Supplied","mono":"<ul><li><b>Kogenate FS<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><li><b>Kogenate FS with BIO-SET<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><li><b>Novoeight<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><li><b>Recombinate<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/><\/li><\/ul>"},"13":{"id":"924955-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug is made from human plasma. Despite screening and testing, human plasma products carry a risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare provider.<\/li><li>Side effects may include injection site reactions and fever.<\/li><li>Advise patient to discontinue use and immediately report signs\/symptoms of hypersensitivity reactions (eg, rash, hives, itching, facial swelling, chest tightness, wheezing, shortness of breath, urticaria).<\/li><li>Instruct patients to report spontaneous bleeding episodes, as this may indicate the development of inhibitory antibodies against factor VIII.<\/li><li>Teach patient proper technique and placement of injections, if appropriate.<\/li><\/ul>"}}}